Newly Diagnosed With DLBCL: First Steps

DLBCL grows quickly. That is why appointments come fast and why the tone can feel alarming. But speed cuts both ways: fast-growing lymphomas respond to chemotherapy, and this one is often cured.

NCI puts it plainly. Most people with localised disease can be cured with combination chemotherapy, with or without radiation. Among people with advanced-stage disease, about half are cured with a doxorubicin-based regimen plus rituximab.

There is a milestone worth holding on to. NCI notes that people with DLBCL who are event-free at two years then have overall survival matching the general population of the same age and sex.

SEER does not report DLBCL separately. For non-Hodgkin lymphoma as a whole, it estimated 79,320 new US cases and 19,970 deaths for 2026, with five-year relative survival of 74.3 percent for 2016 through 2022.

Ask for your International Prognostic Index score. It is built from five things, and each adds points.

• Age: under 40 scores 0, 41 to 60 scores 1, 61 to 75 scores 2, over 75 scores 3.
• Stage III or IV: 1 point.
• Performance status of 2 or worse, meaning limited ability to care for yourself: 1 point.
• Blood LDH: 0 if normal, 1 if up to three times normal, 2 if higher.
• Two or more sites outside the lymph nodes: 1 point.

NCI reports five-year overall survival by band. A score of 0 or 1 gives 96 percent. A score of 2 or 3 gives 82 percent. A score of 4 or 5 gives 64 percent. Scores above 6 give 33 percent.

These are group figures from people treated in past years. They are a planning tool, not a prediction about you.

Some of the early testing is not about the lymphoma at all. It is about making rituximab safe.

NCI describes screening for HIV, and assessment for active hepatitis B and hepatitis C, before rituximab or chemotherapy. Hepatitis B matters even if you cleared it long ago. People who test negative for the surface antigen but positive for the core antibody can have the virus reawaken. In one study of 326 people, preventive antiviral treatment cut reactivation from 10.8 percent to 2.1 percent.

Two other preventive drugs are usually given alongside rituximab. One guards against shingles and one against a lung infection called Pneumocystis.

If the lymphoma is bulky, with a high uric acid and LDH, ask about tumour lysis syndrome. This is a rush of chemicals released as cells die fast, and it can injure the kidneys. NCI lists alkaline fluids, allopurinol, and rasburicase as the ways to prevent and treat it.

R-CHOP has been the standard for over twenty years. It is rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone.

Pola-R-CHP swaps one drug. Polatuzumab vedotin replaces vincristine, chosen partly to reduce nerve damage. In the POLARIX trial of 879 people with an index score of 2 or higher, 2-year progression-free survival was 76.7 percent with Pola-R-CHP and 70.2 percent with R-CHOP. Overall survival at 2 years was the same in both arms: 88.7 percent with Pola-R-CHP and 88.6 percent with R-CHOP. The FDA approved it after longer follow-up showed continued benefit.

There is a nuance worth asking about. NCI notes the benefit fell mainly to people whose lymphoma was not of germinal centre origin. For germinal centre disease without a double-hit change, it says R-CHOP is a reasonable standard, given more fevers with low white counts and much higher cost with the newer regimen.

You may hear about preventive treatment aimed at the spinal fluid. It is worth knowing that NCI is unconvinced by most of it.

A review of German trial data found intrathecal methotrexate did not reduce the risk of lymphoma in the brain, with the possible exception of testicular involvement. Five retrospective studies and a network meta-analysis of high-dose methotrexate given by vein found no improvement in relapse in the brain either.

NCI says people considered high risk, such as those with testicular, kidney, or adrenal disease, or three or more sites outside the lymph nodes, may still be offered it. But it calls the lack of confirming randomised studies a reason to question the standard. If it is proposed for you, ask which of those situations applies.

• Call 911 or go to an emergency department if your face or neck swells with veins standing out on the chest, especially with breathlessness. A bulky chest mass pressing on the vena cava is a genuine emergency.
• Call 911 or go to an emergency department if breath goes suddenly short, or a severe headache, double vision, or new weakness or numbness arrives.
• Call your care team immediately, at any hour, if the thermometer shows 100.4°F (38°C) or over, or chills take hold. Low white counts are common after R-CHOP, and the shingles and Pneumocystis medicines you were given do not cover everything. CDC counts a fever on chemotherapy as a medical emergency, so make that call there and then rather than leaving a message with the clinic. If no one answers quickly, go to an emergency department.
• Call your care team the same day if you are barely passing urine, your muscles cramp, or your heart races in the first days of treatment. With bulky disease and a high LDH, this can be tumour lysis syndrome, which injures the kidneys.
• Call your care team the same day if your eyes or skin yellow, or your urine darkens, at any point after rituximab. Hepatitis B can wake up long after it was cleared.
• Call your care team within a day or two if a lump grows noticeably over days, or drenching night sweats and unexplained weight loss begin.

Diffuse Large B-Cell Lymphoma (DLBCL), What Is R-CHOP Chemotherapy?, Lymphoma Treatment by Stage and Type, and Transplant vs CAR T-Cell Therapy.

• https://www.cancer.gov/types/lymphoma/hp/aggressive-b-cell-lymphoma-treatment-pdq
• https://seer.cancer.gov/statfacts/html/nhl.html
• https://www.cdc.gov/cancer-preventing-infections/patients/fever.html